A Phase 1 interventional study of BMS-986278 and Pirfenidone in Idiopathic Pulmonary Fibrosis (IPF), sponsored by Bristol-Myers Squibb. Completed at 1 site in United States. Open to participants aged 21 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-05-15.
Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies testing pirfenidone in Idiopathic Pulmonary Fibrosis — 2 open to participants now, 3 under way, 1 of them phase 3. pirfenidone · Idiopathic Pulmonary Fibrosis.
Among the 21 studies testing pirfenidone in Idiopathic Pulmonary Fibrosis, this one is the 19th largest by enrollment, is the only one that started in 2019, is one of 5 in phase 1, and was the 14th registered.
577 studies on the registry are indexed under Idiopathic Pulmonary Fibrosis; 124 are open to participants now.
Browse Idiopathic Pulmonary Fibrosis studies →2 of the 21 studies testing pirfenidone in Idiopathic Pulmonary Fibrosis are open now, in 3 countries. Recruiting first, the newest first:
PureTech · Sites in United States, Canada
Ages 40+
Assiut University · Sites in Egypt
Ages 18–80
By country, each count listing its studies:
pirfenidone: first FDA approval 2014 (ESBRIET), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 86 Idiopathic Pulmonary Fibrosis studies recruiting now, 56 (65%) set no upper age limit and 8 (9%) stop at 75 or younger; 3 take children under 18; 15 take healthy volunteers.
This study: 21 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 1 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 22 is below the median of 55 across 390 interventional studies indexed under Idiopathic Pulmonary Fibrosis.
Median enrollment 89 across the 21 interventional studies. Of the 17 that completed or were terminated, 9 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 21 have an industry lead sponsor. The 10 most frequent:
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
11 studies in Idiopathic Pulmonary Fibrosis by Bristol-Myers Squibb: 2 open now, 3 under way, 2 of them phase 3. Of 8 finished, 3 (38%) have results posted.
Among the 11 studies in Idiopathic Pulmonary Fibrosis by Bristol-Myers Squibb, this one is the 9th largest by enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2019, is one of 4 in phase 1, and was the 4th registered.
Bristol-Myers Squibb’s Idiopathic Pulmonary Fibrosis studies by the year they started, since 2011.
1 of the studies testing pirfenidone in Idiopathic Pulmonary Fibrosis that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05842681Assiut UniversityAzithromycin in the Management of Patients With Acute Exacerbation of Idiopathic Pulmonary Fibrosis | 2027-01-01 |
Add it to your calendar (.ics) → With an account.
Among the 21 studies testing pirfenidone in Idiopathic Pulmonary Fibrosis, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Bristol-Myers Squibb’s 11 in Idiopathic Pulmonary Fibrosis:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The main objectives of this study are to characterize the PK of BMS-986278 after administration of a single dose of BMS-986278 alone or in combination with pirfenidone, as well as to characterize the PK of pirfenidone after administration of a single dose of pirfenidone alone or in combination with BMS-986278
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol defined inclusion/exclusion criteria could apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: BMS-986278
Drug: Pirfenidone
Drug: BMS-986278 · Drug: Pirfenidone
suspension
capsule
Maximum observed serum concentration (Cmax) of BMS-986278 and pirfenidone alone or in combination
Time frame: Up to day 5 of each period (Each period is 7 days; 3 periods total)
Area under the serum concentration-time curve from time zero to time of last quantifiable concentration [AUC(0-T)] of BMS-986278 and pirfenidone alone or in combinaton
Time frame: Up to day 5 of each period (Each period is 7 days; 3 periods total)
Area under the plasma concentration-time curve extrapolated to infinity [(AUC(INF)] of BMS-986278 and pirfenidone alone or in combinaton
Time frame: Up to day 5 of each period (Each period is 7 days; 3 periods total)
Incidence of AEs (adverse events), SAEs (serious adverse events), and AEs leading to discontinuation
Time frame: Up to Day 8 of Period 3 (each period is 7 days; 3 periods total)
Number of Participants With Clinically Significant Change in Clinical Laboratory Values
Time frame: Up to Day 8 of Period 3 (each period is 7 days; 3 periods total)
Number of Participants With Clinically Significant Change in Vital Signs
Time frame: Up to Day 8 of Period 3 (each period is 7 days; 3 periods total)
Number of Participants With Clinically Significant Change in Electrocardiogram (ECG)
Time frame: Up to Day 8 of Period 3 (each period is 7 days; 3 periods total)
Number of Participants With Clinically Significant Change in Physical Examination
Time frame: Up to Day 8 of Period 3 (each period is 7 days; 3 periods total)
Volume of distribution at terminal phase (VzF) of BMS-986278 and metabolite alone or in combination with pirfenidone
Time frame: Up to Day 5 of period 3 (each period is 7 days; 3 periods total)
Time of maximum observed serum concentration (Tmax) of BMS-986278 and metabolite alone or in combination with pirfenidone
Time frame: Up to Day 5 of period 3 (each period is 7 days; 3 periods total)
Elimination half-life (T-HALF) of BMS-986278 and metabolite alone or in combination with pirfenidone
Time frame: Up to Day 5 of period 3 (each period is 7 days; 3 periods total)
Oral clearance (CL/F) of BMS-986278 and metabolite alone or in combination with pirfenidone
Time frame: Up to Day 5 of period 3 (each period is 7 days; 3 periods total)
Time of maximum observed serum concentration (Tmax) of pirfenidone and metabolite alone or in combination with BMS-986278
Time frame: Up to Day 5 of Period 3 (each period is 7 days; 3 periods total)
Elimination half-life (T-HALF) of pirfenidone and metabolite alone or in combination with BMS-986278
Time frame: Up to Day 5 of Period 3 (each period is 7 days; 3 periods total)
Oral clearance (CL/F) of pirfenidone and metabolite alone or in combination with BMS-986278
Time frame: Up to Day 5 of Period 3 (each period is 7 days; 3 periods total)
Volume of distribution at terminal phase (VzF) Plasma Pharmokinetics of pirfenidone and metabolite alone or in combination with BMS-986278
Time frame: Up to Day 5 of Period 3 (each period is 7 days; 3 periods total)
Renal clearance (Clr) in Urine of pirfenidone alone or in combination with BMS-986278
Time frame: Up to Day 5 of Period 3 (each period is 7 days; 3 periods total)
Cumulative amount recovered in urine [Ae(0-T)] of pirfenidone alone or in combination with BMS-986278
Time frame: Up to Day 5 of Period 3 (each period is 7 days; 3 periods total)
Ran from May 2019 to primary completion in Jul 2019, 2 months.
Of 60 industry-sponsored phase 1 interventional studies under Idiopathic Pulmonary Fibrosis, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 16. This study's 2 months is below that.
Counting every sponsor, half of 75 studies reached it within 12 months; a quarter within 5 and three quarters within 23.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Admilparant · Pirfenidone
Idiopathic Pulmonary Fibrosis →